Compare · LGND vs VKTX
LGND vs VKTX
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LGND is the larger of the two at $4.75B, about 1.4x VKTX ($3.30B).
- Over the past year, LGND is up 123.6% and VKTX is up 2.2% - LGND leads by 121.3 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- VKTX has more recent analyst coverage (23 ratings vs 9 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Viking Therapeutics Inc.
- Price
- $237.54+0.65%
- $28.45-4.42%
- Market cap
- $4.75B
- $3.30B
- 1M return
- +2.46%
- -11.84%
- 1Y return
- +123.57%
- +2.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 8
- Recent ratings
- 9
- 23
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest LGND
- CLO & Secretary Reardon Andrew sold $1,135,316 worth of shares (5,000 units at $227.06) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)
- Chief Financial Officer Espinoza Octavio exercised 1,736 shares at a strike of $57.58, increasing direct ownership by 7% to 27,679 units (SEC Form 4)
- Ligand to Participate in June Investor Conferences
- SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated
- SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated
- Director Kozarich John W sold $563,080 worth of shares (2,501 units at $225.14) as part of a pre-agreed trading plan and exercised 2,034 shares at a strike of $69.51, decreasing direct ownership by 1% to 41,786 units (SEC Form 4)
- SEC Form 144 filed by Ligand Pharmaceuticals Incorporated
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest VKTX
- SEC Form 4 filed by Chief Medical Officer Chen Hubert C
- SEC Form 3 filed by new insider Chen Hubert C
- Lake Street initiated coverage on Viking Therapeutics with a new price target
- Truist resumed coverage on Viking Therapeutics with a new price target
- Viking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
- Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
- Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
- SEC Form 10-Q filed by Viking Therapeutics Inc.